Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (Weighted Average) (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Shares Outstanding (Weighted Average) data on record, last reported at $72.1 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 1.58% year-over-year to $72.1 million; the TTM value through Sep 2025 reached $72.1 million, up 1.58%, while the annual FY2024 figure was $71.1 million, 8.67% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $72.1 million in Q3 2025 per ZNTL's latest filing, roughly flat from $71.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $72.1 million in Q3 2025 and bottomed at $45.2 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $63.7 million, with a median of $70.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 38.19% in 2023, then rose 0.57% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $52.9 million in 2022, then grew by 23.75% to $65.4 million in 2023, then increased by 8.67% to $71.1 million in 2024, then rose by 1.49% to $72.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $72.1 million in Q3 2025, $71.8 million in Q2 2025, and $71.7 million in Q1 2025.